Neoadjuvant concurrent chemoradiotherapy followed by transanal total mesorectal excision assisted by single-port laparoscopic surgery for low-lying rectal adenocarcinoma: a single center study
- PMID: 32782005
- PMCID: PMC7422550
- DOI: 10.1186/s12957-020-01980-y
Neoadjuvant concurrent chemoradiotherapy followed by transanal total mesorectal excision assisted by single-port laparoscopic surgery for low-lying rectal adenocarcinoma: a single center study
Abstract
Purpose: To assess the feasibility and short-term outcomes of neoadjuvant chemoradiotherapy (CCRT) followed by transanal total mesorectal excision assisted by single-port laparoscopic surgery (TaTME-SPLS) for low-lying rectal adenocarcinoma.
Methods and materials: A total of 23 patients with clinical stage II-III low-lying (from anal verge 0-8 cm) rectal adenocarcinoma who underwent neoadjuvant CCRT followed by TaTME-SPLS consecutively from December 2015 to December 2018, were enrolled into our study. Chi-squared testing and Student's t testing were used to make parametric comparisons, and Fisher's exact test or the Mann-Whitney U test were used to make nonparametric comparisons.
Results: Conversion rate in patients who underwent neoadjuvant CCRT followed by TaTME-SPLS was only 4%. The mean operation time was 366 min and the inter-sphincter resection (ISR) was done for 14 patients (60%). The mean number of lymph nodes harvested was 15. There was no surgical mortality, but the 30-day morbidity rate was 21% (5 patients were Clavien-Dindo I-II). Pathological complete response was 21.74% with 100% organ preservation and 100% clear distal margin after neoadjuvant CCRT followed by TaTME-SPLS.
Conclusion: TaTME-SPLS would be highly successful in lymph node negative and low T stage of low-lying rectal cancer patients who had pathological complete remission or high percentage of partial remission after neoadjuvant CCRT.
Keywords: Neoadjuvant CCRT; Rectal adenocarcinoma; TaTME-SPLS.
Conflict of interest statement
The author(s) declare no potential conflicts of interest.
Similar articles
-
Comparison of transanal total mesorectal excision and robotic total mesorectal excision for low rectal cancer after neoadjuvant chemoradiotherapy.Surg Endosc. 2021 Dec;35(12):6998-7004. doi: 10.1007/s00464-020-08213-z. Epub 2021 Feb 1. Surg Endosc. 2021. PMID: 33523275
-
Transanal total mesorectal excision (taTME) for cancer located in the lower rectum: short- and mid-term results.Eur J Surg Oncol. 2015 Apr;41(4):478-83. doi: 10.1016/j.ejso.2015.01.009. Epub 2015 Jan 17. Eur J Surg Oncol. 2015. PMID: 25633642
-
Transanal Total Mesorectal Excision Versus Laparoscopic Surgery for Rectal Cancer Receiving Neoadjuvant Chemoradiation: A Matched Case-Control Study.Ann Surg Oncol. 2016 Apr;23(4):1169-76. doi: 10.1245/s10434-015-4997-y. Epub 2015 Nov 23. Ann Surg Oncol. 2016. PMID: 26597369
-
Comparison of short-term clinical outcomes between transanal and laparoscopic total mesorectal excision for the treatment of mid and low rectal cancer: A meta-analysis.Eur J Surg Oncol. 2016 Dec;42(12):1841-1850. doi: 10.1016/j.ejso.2016.09.002. Epub 2016 Sep 19. Eur J Surg Oncol. 2016. PMID: 27697315 Review.
-
Meta-analysis of transanal total mesorectal excision versus laparoscopic total mesorectal excision in management of rectal cancer.Int J Colorectal Dis. 2020 Apr;35(4):575-593. doi: 10.1007/s00384-020-03545-7. Epub 2020 Mar 2. Int J Colorectal Dis. 2020. PMID: 32124047
Cited by
-
Impact of Adjuvant Chemotherapy Following Neoadjuvant Concurrent Chemoradiotherapy and Total Mesorectal Excision in Rectal Cancer.In Vivo. 2025 Jul-Aug;39(4):2311-2319. doi: 10.21873/invivo.14027. In Vivo. 2025. PMID: 40579008 Free PMC article.
References
-
- Nelson H, Sargent DJ, Wieand HS, Fleshman J, Anvari M, Stryker SJ, Beart RW, Jr, Hellinger M, Flanagan R, Jr, Peters W, Ota D. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med. 2004;350:2050–2059. - PubMed
-
- Leung KL, Kwok SP, Lam SC, Lee JF, Yiu RY, Ng SS, Lai PB, Lau WY. Laparoscopic resection of rectosigmoid carcinoma: prospective randomised trial. Lancet. 2004;363:1187–1192. - PubMed
-
- Lacy AM, Garcia-Valdecasas JC, Delgado S, Castells A, Taura P, Pique JM, Visa J. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet. 2002;359:2224–2229. - PubMed
-
- Bonjer HJ, Deijen CL, Haglind E. A randomized trial of laparoscopic versus open surgery for rectal cancer. N Engl J Med. 2015;373:194. - PubMed
-
- Jeong SY, Park JW, Nam BH, Kim S, Kang SB, Lim SB, Choi HS, Kim DW, Chang HJ, Kim DY, et al. Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial. Lancet Oncol. 2014;15:767–774. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources